Breast cancer subtypes and outcome after local and regional relapse

被引:62
作者
Montagna, E. [1 ]
Bagnardi, V. [2 ,3 ,4 ]
Rotmensz, N. [2 ]
Viale, G. [5 ,6 ]
Renne, G. [5 ,6 ]
Cancello, G.
Balduzzi, A.
Scarano, E.
Veronesi, P. [5 ,7 ]
Luini, A. [7 ]
Zurrida, S. [5 ,7 ]
Monti, S. [7 ]
Mastropasqua, M. G. [6 ]
Bottiglieri, L. [6 ]
Goldhirsch, A.
Colleoni, M.
机构
[1] European Inst Oncol, Dept Med, Div Med Oncol, Res Unit Med Senol, I-20141 Milan, Italy
[2] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy
[3] Univ Milano Bicocca, Dept Stat, Milan, Italy
[4] Frontier Sci & Technol Res Fdn So Europe, Chiasso, Switzerland
[5] Univ Milan, Sch Med, Milan, Italy
[6] European Inst Oncol, Div Pathol, I-20141 Milan, Italy
[7] European Inst Oncol, Div Senol, I-20141 Milan, Italy
关键词
breast; cancer; locoregional; relapse; 20-YEAR FOLLOW-UP; RANDOMIZED-TRIAL; RECEPTOR EXPRESSION; CONSERVING SURGERY; TUMOR RECURRENCE; CHEMOTHERAPY; MASTECTOMY; THERAPY; METASTASES; PROGNOSIS;
D O I
10.1093/annonc/mdr129
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To evaluate the outcome of breast cancer patients after locoregional recurrence (LRR) according to tumor biological features evaluated at first diagnosis and at the time of recurrence. Patients and methods: We collected information on all consecutive breast cancer patients operated at the European Institute of Oncology between 1994 and 2005. The tumor characteristics and subsequent outcome of patients who experienced LRR were analyzed. Results: Two hundred and seventy nine patients with LRR were identified, 197 and 82 patients with local and regional recurrence respectively. The overall discordance rate between primary cancer and LRR was 9% for estrogen receptor expression, 22% for progesterone receptor and 4% for human epidermal growth factor receptor 2. For patients with regional recurrence, the risk of distant metastasis was significantly higher compared with local relapse in case of late recurrence (hazard ratio [HR] = 2.76; 95% CI 1.31-5.85). Patients with triple-negative breast cancer at LRR experienced a higher risk of subsequent relapse (HR 2.87 [1.67-4.91]) and death (HR 2.00 [1.25-3.19]). Conclusion: LRR correlates with a high risk of subsequent events and death in particular in patients with triple-negative subtype.
引用
收藏
页码:324 / U299
页数:8
相关论文
共 27 条
  • [1] [Anonymous], 2011, The statistical analysis of failure time data
  • [2] Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer:: 20-year follow-up of the Danish randomized DBCG-82TM protocol
    Blichert-Toft, Mogens
    Nielsen, Maja
    Duering, Maria
    Moller, Susanne
    Rank, Fritz
    Overgaard, Marie
    Mouridsen, Henning T.
    [J]. ACTA ONCOLOGICA, 2008, 47 (04) : 672 - 681
  • [3] Local recurrence after mastectomy for breast cancer:: analysis of clinicopathological, biological and prognostic characteristics
    Carreno, Guillermo
    del Casar, Jose M.
    Corte, Ma Daniela
    Gonzalez, Luis O.
    Bongera, Miguel
    Merino, Antonio M.
    Juan, German
    Obregon, Raul
    Martinez, Enrique
    Vizoso, Francisco J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (01) : 61 - 73
  • [4] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
    Cheang, Maggie C. U.
    Chia, Stephen K.
    Voduc, David
    Gao, Dongxia
    Leung, Samuel
    Snider, Jacqueline
    Watson, Mark
    Davies, Sherri
    Bernard, Philip S.
    Parker, Joel S.
    Perou, Charles M.
    Ellis, Matthew J.
    Nielsen, Torsten O.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10): : 736 - 750
  • [5] Prediction of response to primary chemotherapy for operable breast cancer
    Colleoni, M
    Orvieto, E
    Nolé, F
    Orlando, L
    Minchella, I
    Viale, G
    Peruzzotti, G
    Robertson, C
    Noberasco, C
    Galimberti, V
    Sacchini, V
    Veronesi, P
    Zurrida, S
    Orecchia, R
    Goldhirsch, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (04) : 574 - 579
  • [6] Identifying breast cancer patients at high risk for bone metastases
    Colleoni, M
    O'Neill, A
    Goldhirsch, A
    Gelber, RD
    Bonetti, M
    Thürlimann, B
    Price, KN
    Castiglione-Gertsch, M
    Coates, AS
    Lindtner, J
    Collins, J
    Senn, HJ
    Cavalli, F
    Forbes, J
    Gudgeon, A
    Simoncini, E
    Cortes-Funes, H
    Veronesi, A
    Fey, M
    Rudenstam, CM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) : 3925 - 3935
  • [7] Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer
    Colleoni, Marco
    Cole, Bernard F.
    Viale, Giuseppe
    Regan, Meredith M.
    Price, Karen N.
    Maiorano, Eugenio
    Mastropasqua, Mauro G.
    Crivellari, Diana
    Gelber, Richard D.
    Goldhirsch, Aron
    Coates, Alan S.
    Gusterson, Barry A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18) : 2966 - 2973
  • [8] COX DR, 1972, J R STAT SOC B, V34, P187
  • [9] Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response
    de Ronde, Jorma J.
    Hannemann, Juliane
    Halfwerk, Hans
    Mulder, Lennart
    Straver, Marieke E.
    Peeters, Marie-Jeanne T. F. D. Vrancken
    Wesseling, Jelle
    van de Vijver, Marc
    Wessels, Lodewyk F. A.
    Rodenhuis, Sjoerd
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 119 - 126
  • [10] Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer
    Fisher, B
    Anderson, S
    Bryant, J
    Margolese, RG
    Deutsch, M
    Fisher, ER
    Jeong, J
    Wolmark, N
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (16) : 1233 - 1241